Effect of FHIT loss and p53 mutation on HPV-infected lung carcinoma development

Yu,Yan; Liu,Xiaofei; Yang,Yuxuan; Zhao,Xiaodan; Xue,Jianjun; Zhang,Weixiao; Yang,Aimin

doi:10.3892/ol.2015.3213

Effect of FHIT loss and p53 mutation on HPV-infected lung carcinoma development

Authors:
- Yan Yu
- Xiaofei Liu
- Yuxuan Yang
- Xiaodan Zhao
- Jianjun Xue
- Weixiao Zhang
- Aimin Yang
View Affiliations

Affiliations: Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Nuclear Medicine, The First Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: May 15, 2015 https://doi.org/10.3892/ol.2015.3213
Pages: 392-398

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High-risk human papillomavirus (HPV)16/18 infection in the development of lung cancer has previously been identified, and fragile histidine triad (FHIT) loss and p53 mutation are frequently observed in the disease. However, the association between these factors has not been well studied. The present study aimed to further investigate the significance of HPV infection, FHIT loss and p53 mutations in the development of lung cancer and their possible associations. DNA was extracted from paraffin‑embedded specimens from 88 cases of squamous cell carcinoma (SCC), 56 of adenocarcinoma (AC), 36 of small cell lung carcinoma (SCLC) and 110 non‑cancer control cases of lung neoplasms. The prevalence of HPV infection was determined by polymerase chain reaction analysis, and FHIT loss and p53 mutations were detected by immunohistochemistry. The χ2, Fisher's exact and Pearson correlation tests were applied for statistical analysis. The results of the present study demonstrated that HPVL1 (the major capsid protein of HPV), HPV16 and HPV18 infection were more prevalent in the lung cancer samples compared with the non‑cancer controls (all P<0.001). FHIT loss occurred more frequently in the lung cancer samples (44.44%) compared with the non‑cancer controls (7.25%) (P<0.001). FHIT loss in the HPVL1‑positive group was significantly increased compared with the HPVL1‑negative group in the lung cancer cases and the non‑cancer controls (P<0.05). In the lung cancer cases, the p53 mutation rates in the HPVL1‑ and HPV16/18‑positive groups were significantly increased compared with the HPVL1‑ and HPV16/18‑negative groups (P<0.05). In the 180 lung cancer cases, the coexistence rate of FHIT loss and a history of smoking was 38.33% (69/180; Pearson contingency coefficient of r=0.318; P<0.001). FHIT loss and p53 mutation exhibited a synergistic effect on HPV‑associated lung cancer (Pearson contingency coefficient r=0.357, P<0.001). The present study demonstrated that FHIT loss may be important in the occurrence of lung cancer, particularly in lung SCCs. FHIT loss may therefore be used as an early indicator for lung cancer, particularly for patients with a history of smoking. HPV infection in lung tumorigenesis may, at least in part, be mediated through FHIT loss. FHIT loss and p53 mutation may coordinate together in the development of HPV-associated lung cancer, and accelerate the occurrence and development of lung cancer.

View Figures

View References

1	Al-Badawi IA, Al-Suwaine A, Al-Aker M, Asaad L, Alaidan A, Tulbah A, Fe Bohol M and Munkarah AR: Detection and genotyping of human papilloma virus in cervical cancer specimens from Saudi patients. Int J Gynecol Cancer. 21:907–910. 2011. View Article : Google Scholar : PubMed/NCBI
2	Al-Shabanah OA, Hafez MM, Hassan ZK, Sayed-Ahmed MM, Abozeed WN, Al-Rejaie SS and Alsheikh AA: Human papillomavirus genotyping and integration in ovarian cancer Saudi patients. Virol J. 10:343–352. 2013. View Article : Google Scholar : PubMed/NCBI
3	Yang X and Lu L: Expression of HPV-16 E6 protein and p53 inactivation increases the uterine cervical cancer invasion. Drug Res (Stuttg). 65:70–73. 2015.PubMed/NCBI
4	Aumayr K, Susani M, Horvat R, Wrba F, Mazal P, Klatte T, Koller A, Neudert B and Haitel A: P16INK4A immunohistochemistry for detection of human papilloma virus-associated penile squamous cell carcinoma is superior to in-situ hybridization. Int J Immunopathol Pharmacol. 26:611–620. 2013.PubMed/NCBI
5	Sarchianaki E, Derdas SP, Ntaoukakis M, et al: Detection and genotype analysis of human papillomavirus in non-small cell lung cancer patients. Tumour Biol. 35:3203–3209. 2014. View Article : Google Scholar : PubMed/NCBI
6	Yu Y, Yang A, Hu S and Yan H: Correlation of HPV-16/18 infection of human papillomavirus with lung squamous cell carcinomas in Western China. Oncol Rep. 21:1627–1632. 2009.PubMed/NCBI
7	Jafari H, Gharemohammadlou R, Fakhrjou A, et al: Genotyping of human papillomavirus and TP53 mutations at exons 5 to 7 in lung cancer patients from Iran. Bioimpacts. 3:135–140. 2013.PubMed/NCBI
8	Ragin C, Obikoya-Malomo M, Kim S, et al: HPV-associated lung cancers: An international pooled analysis. Carcinogenesis. 35:1267–1275. 2014. View Article : Google Scholar : PubMed/NCBI
9	Hasegawa Y, Ando M, Kubo A, Isa S, Yamamoto S, Tsujino K, Kurata T, Ou SH, Takada M and Kawaguchi T: Human papilloma virus in non-small cell lung cancer in never smokers: A systematic review of the literature. Lung Cancer. 83:8–13. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ohta M, Inoue H, Cotticelli MG, et al: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 84:587–597. 1996. View Article : Google Scholar : PubMed/NCBI
11	Wistuba II, Montellano FD, Milchgrub S, et al: Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res. 57:3154–3158. 1997.PubMed/NCBI
12	Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI and Glover TW: FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: Direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet. 5:187–195. 1996. View Article : Google Scholar : PubMed/NCBI
13	Wang J, Cheng YW, Wu DW, Chen JT, Chen CY, Chou MC and Lee H: Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan. Cancer Lett. 235:18–25. 2006. View Article : Google Scholar : PubMed/NCBI
14	Yu Y, Yang A, Hu S, Zhang J and Yan H: Significance of human papillomavirus 16/18 infection in association with p53 mutation in lung carcinomas. Clin Respir J. 7:27–33. 2013. View Article : Google Scholar : PubMed/NCBI
15	Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M and Huh K: Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 78:11451–11460. 2004. View Article : Google Scholar : PubMed/NCBI
16	Greer CE, Wheeler CM and Manos MM: PCR amplification from paraffin-embedded tissues: sample preparation and the effects of fixationPCR Primer: a laboratory manual. Carl WD and Gabriela SD: Cold Spring Harbor Laboratory Press; New York: pp. 99–112. 1995
17	Wang JL, Fang CL, Wang M, Yu MC, Bai KJ, Lu PC and Liu HE: Human papillomavirus infections as a marker to predict overall survival in lung adenocarcinoma. Int J Cancer. 134:65–71. 2014. View Article : Google Scholar : PubMed/NCBI
18	Badillo-Almaraz I, Zapata-Benavides P, Saavedra-Alonso S, Zamora-Avila D, Reséndez-Pérez D, Tamez-Guerra R, Herrera-Esparza R and Rodríguez-Padilla C: Human papillomavirus 16/18 infections in lung cancer patients in Mexico. Intervirology. 56:310–315. 2013. View Article : Google Scholar : PubMed/NCBI
19	Iwakawa R, Kohno T, Enari M, Kiyono T and Yokota J: Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma. Cancer Sci. 101:1891–1896. 2010. View Article : Google Scholar : PubMed/NCBI
20	Bahnassy AA, Zekri AR, Madbouly MS, El-Naggar M, El-Khelany ZF and El-Merzebany MM: The correlation between FHIT, P53 and MMR genes in human papillomavirus-associated cervical carcinoma. J Egypt Natl Canc Inst. 18:191–202. 2006.PubMed/NCBI
21	Giarnieri E, Zanesi N, Bottoni A, Alderisio M, Lukic A, Vecchione A, Ziparo V, Croce CM and Mancini R: Oncosuppressor proteins of fragile sites are reduced in cervical cancer. Cancer Lett. 289:40–45. 2010. View Article : Google Scholar : PubMed/NCBI
22	Sozzi G, Veronese ML, Neghni M, et al: The FHIT gene 3p14.2 is abnormal in lung cancer. Cell. 85:17–26. 1996. View Article : Google Scholar : PubMed/NCBI
23	Kapitanović S, Čačev T, Lončar B, Catela Ivković T, Križanac Š and Pavelić K: Reduced FHIT expression is associated with tumor progression in sporadic colon adenocarcinoma. Exp Mol Pathol. 96:92–97. 2014. View Article : Google Scholar : PubMed/NCBI
24	Stein CK, Glover TW, Palmer JL and Glisson BS: Direct correlation between FRA3B expression and cigarette smoking. Genes Chromosomes Cancer. 34:333–340. 2002. View Article : Google Scholar : PubMed/NCBI
25	Neyaz MK, Hussain S, Hassan MI, et al: Novel missense mutation in FHIT gene: Interpreting the effect in HPV-mediated cervical cancer in Indian women. Mol Cell Biochem. 335:53–58. 2010. View Article : Google Scholar : PubMed/NCBI